Alnylam's gene-blocker study may help assuage safety worries

09/27/2007 | Bloomberg1

Alnylam Pharmaceutical's latest animal study may ease safety concerns over its experimental drugs derived from RNA interference, the company said. Researchers found that Alnylam's gene-blocking molecules were able to block about 80% of the genes' effects on mice without disturbing a critical cell regulation system.

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA